Embecta Corp Intrinsic Value – EMBECTA CORP Reports Impressive Q2 Earnings with Non-GAAP EPS of $0.59, Revenue of $281.9M
December 10, 2023
☀️Trending News
EMBECTA ($NASDAQ:EMBC): This is an impressive increase compared to the estimated $0.40 and $271.55M respectively. The $0.19 beat in EPS and the additional $10.35M in revenue was clear evidence of the company’s excellence in the second quarter. The company has invested heavily in research and development, allowing them to stay ahead of their competition and continuously improve their products.
Additionally, they have successfully launched new products that have been well-received by customers, contributing to their impressive revenue growth. With their successful investments in R&D and innovative products, they are poised to continue to exceed expectations and lead the industry in the years to come.
Earnings
This represents a 1.3% increase in total revenue and a 67.8% increase in net income compared to the same quarter of the previous year. In the last three years, total revenue has declined from $295.0M to $286.1M USD, illustrating the importance of continued strong performance to maintain profitability.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Embecta Corp. More…
| Total Revenues | Net Income | Net Margin |
| 1.12k | 70.4 | 6.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Embecta Corp. More…
| Operations | Investing | Financing |
| 67.7 | -26.5 | -48.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Embecta Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.21k | 2.04k | -14.33 |
Key Ratios Snapshot
Some of the financial key ratios for Embecta Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1.1% | -22.8% | 19.0% |
| FCF Margin | ROE | ROA |
| 3.7% | -16.3% | 10.9% |
Price History
The news of the strong earnings caused the stock to open at $16.0 and close at $17.1, up by 4.5% from prior closing price of 16.3. This is a sign that the market is optimistic about the company’s future prospects and investors are confident about the company’s ability to generate returns. Live Quote…
Analysis – Embecta Corp Intrinsic Value
At GoodWhale, we recently conducted an analysis of EMBECTA CORP‘s wellbeing. Through our proprietary Valuation Line, we determined that the fair value of EMBECTA CORP’s share is around $31.3. However, currently EMBECTA CORP stock is being traded at $17.1, which is undervalued by 45.4%. Therefore, we believe that EMBECTA CORP has a strong upside potential for investors. More…
Peers
The company was founded in 1980 and is headquartered in New York, NY. Embecta Corp‘s products include prescription drugs for the treatment of cardiovascular disease, diabetes, and cancer. The company’s competitors include Uluru Inc, RxSight Inc, and Modalis Therapeutics Corp.
– Uluru Inc ($OTCPK:ULUR)
RxSight Inc is a medical device company that develops and commercializes innovative ophthalmic implants that allow ophthalmologists to more precisely treat complex retinal diseases. As of 2022, the company has a market capitalization of 318.4 million and a return on equity of -31.3%.
– RxSight Inc ($NASDAQ:RXST)
Modalis Therapeutics Corp is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and other diseases. The company has a market cap of 11.21B as of 2022 and a return on equity of -13.14%. Modalis Therapeutics Corp is headquartered in New York, New York.
Summary
EMBECTA Corp. is a technology company that recently reported their quarterly financials. The company beat expectations with a non-GAAP EPS of $0.59, beating the expected $0.40 by $0.19. As a result of these impressive results, investors responded positively and the stock price moved up the same day. This is encouraging news and suggests that investors have confidence in EMBECTA’s business strategy and growth potential.
Related Posts
Recent Posts
